Empowered Patient Podcast

Ayla Annac, CEO and Co-Founder, InvivoSciences shines light on the next generation of precision medicine and explains how IVS is personalizing the drug development process with patient-derived and gene-edited human samples.  The company's Novel Heart Tissue on a chip platform NuHeart™ enables rapid identification of the safety and efficacy profile of a given treatment for a specific patient group.  IVS is saving time and money in developing new therapies while increasing the success rate of approval for cardio safe therapies. #COVID19 #ChronicHeartFailure InvivoSciences.com Download the transcript here